# Trial of DB289 for the Treatment of Stage I African Trypanosomiasis

> **NCT00803933** · PHASE2 · COMPLETED · sponsor: **Immtech Pharmaceuticals, Inc** · enrollment: 111 (actual)

## Conditions studied

- African Trypanosomiasis

## Interventions

- **DRUG:** DB289
- **DRUG:** Pentamidine

## Key facts

- **NCT ID:** NCT00803933
- **Lead sponsor:** Immtech Pharmaceuticals, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-02
- **Primary completion:** 2004-02
- **Final completion:** 2005-06
- **Target enrollment:** 111 (ACTUAL)
- **Last updated:** 2008-12-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00803933

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00803933, "Trial of DB289 for the Treatment of Stage I African Trypanosomiasis". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT00803933. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*
